Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 7.32%, which has investors questioning if this is right time to buy.

Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 12.39%, which has investors questioning if this is right time ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.

Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and ...

A Houston-area company has just inked a massive, $1 billion deal to become the next big weight-loss medication maker. Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will ...

As uncertainties surrounding trade policies, fresh recession fears, and persistent inflation kept the markets on tenterhooks throughout the past week, a handful of small-caps defied the odds by ...

Novo Nordisk (NOV: N) has reported new Phase IIIb data showing its GLP-1 drug semaglutide, in both oral and injectable forms, led to significant health benefits in adults with type 2 diabetes facing ...

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for the preclinical obesity drug LX9851. The company abandoned its underperforming heart failure drug and ...